Skin lesions induced by bortezomib.
We report on six cases of skin lesions induced by bortezomib in patients treated for relapsed multiple myeloma. The folliculitis-like rash appeared in the second cycle of bortezomib therapy. Therapy with prednisone led to rapid resolution of the skin lesions. Prednisone 10 mg before each infusion of bortezomib was necessary to prevent recurrence of the rash while antihistamines alone were ineffective.
Pour
Ludek
L
Department of Internal Medicine-Hematooncology , Masaryk University Hospital, Jihlavska 20, Brno, 625 00, Czech Republic. lpour@fnbrno.cz
Hajek
Roman
R
Zdenek
Adam
A
Krejci
Marta
M
Krivanova
Andrea
A
Vorlicek
Jiri
J
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D017332:Cetirizine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D011241:Prednisone / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D016879:Salvage Therapy
D000970:Antineoplastic Agents; D001897:Boronic Acids; D039563:Histamine H1 Antagonists, Non-Sedating; D007166:Immunosuppressive Agents; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D011241:Prednisone; D017332:Cetirizine